Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201408-11 Anti-cancer antibody therapeutics, anti-AITR(Oncology, Protein) [03.04.2015]

PRINT

Development and Market Objectives

Anti-AITR has been characterized in human PBMC and humanized mouse model. It polarized Teff to Th1 and converted Treg to Th1, and suppressed human cancers in HLA-match humanized mice. We plan to develop the antibody as an anti-cancer drug by taking steps of nonclinical and clinical trials.

Unmet Medical Need & Target Patients

Our newly developed anti-AITR converts Treg to Teff cells, and then activates effector T cells, which enables to trigger potent and comprehensive anti-tumor activities, and thus provide therapeutic effects for all types of hematologic and solid cancers.  

Status

The antibodies are being validated and optimized.

Intellectual Property

Patents are being applied

Competitive Advantages

Polarization of Treg to Th1 and activation of CD8+ T cells

Indication

Oncology

Research Period

2015.2.1-2017.6.30

Company

Eutilex Co., LTD.

Developmental Stage

Optimization

Additional Information

Contact Information

Contact
Address Company Name: Eutilex Co., LTD.
WebSite Homepage: http://eutilex.com/eng/home.php Contact Person: Seung Joo Lee
E-mail: lees1111@eutilex.com Contact: 82-70-4165-7432

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code